BBT Capital Management’s Amedisys AMED Stock Holding History

BBT Capital Management’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,396	Closed	-$295K	–	173
2019 Q1	$295K	Buy	+2,396	New	+$301K	0.37%	86

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

BBT Capital Management's AMED Position: Q2 2019 in Review

BBT Capital Management sold out of Amedisys (AMED) in Q2 2019, closing a stake of 2,396 shares — an estimated $295K sold.

BBT Capital Management first reported a position in AMED in Q1 2019 and held it in 1 quarter. The position peaked at $295K in Q1 2019. 285 funds tracked by Wall St. Rank hold AMED as of Q2 2019.

BBT Capital Management reported no remaining Amedisys position as of Q2 2019 after selling out during the quarter.
BBT Capital Management sold 2,396 Amedisys shares in Q2 2019, an estimated $295K.
BBT Capital Management first reported a position in Amedisys in Q1 2019 and held it in 1 quarter.
BBT Capital Management's Amedisys position peaked at $295K in Q1 2019.
285 funds tracked by Wall St. Rank held Amedisys as of Q2 2019.

Based on BBT Capital Management's 13F filing for Q2 2019, filed 9 Aug 2019.